Women Are Underrepresented in NSCLC Clinical Trials
Women are underrepresented in clinical trials of NSCLC treatment, a meta-analysis suggests.
Women are underrepresented in clinical trials of NSCLC treatment, a meta-analysis suggests.
Findings suggest link to more aggressive disease among estrogen users, but researchers say larger studies needed.
A recent study found a racial disparity in the use of guideline-concordant treatment for metastatic prostate cancer.
Compared with White patients, Black patients have 71 percent higher odds of cardiotoxicity.
Cancer survivors may be more likely to delay or forgo care if their treating clinician is of a different race, gender, or other identity, a new study suggests.
Researchers sought to identify the factors that resulted in a high proportion of African American patients with multiple myeloma participating in the Winship clinical trials.
Patients with MCC may have different sites of disease, stage at diagnosis, and survival outcomes according to their racial or ethnic group.
A survey study explored demographic factors that influence patient understanding of genomic tumor testing.
Seventeen variants identified as potentially oncogenic in 17.7 percent of South African male patients.
Survivors with four to seven types of discrimination events had large, clinically meaningful increase in deficits.